Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2C-T-7** is a synthetic psychedelic phenethylamine belonging to the "2C" family. It acts primarily as an agonist at serotonin receptors—especially the serotonin 5-HT₂A receptor—producing hallucinogenic and entactogenic effects. The compound was first described by Alexander Shulgin in his book PiHKAL. Effects typically last between eight and fifteen hours when taken orally. There is no accepted medical use for this substance; it has been associated with several fatalities and is classified as a Schedule I controlled substance in the United States due to its high potential for abuse and lack of accepted safety or therapeutic application[1][3][6]. Its mechanism of action involves serotonergic activity at central nervous system receptors implicated in hallucinogenic effects[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2C-T-7.